黑料网

Abstract

The development of ranolazine mouth dissolving films (MDFs), which are used to treat angina pectoris in cardiovascular illnesses, is the primary goal of the current study. Using the solvent casting method, eight formulations (F1, F2, F3, F4, F5, F6, F7, F8) were made using HPMC E15 and PVA as polymers, PEG 400 as a plasticizer, sugar as a sweetener, citric acid as a saliva-stimulating agent, and mint as a flavoring ingredient. The produced films are taken without the use of water, have a rapid onset of action, and boost bioavailability by avoiding hepatic first pass metabolism. Formulation F3 was determined to be stable under appropriate stability conditions, with a drug release rate of 94.34% in just 5 minutes. The assessment criteria of the films indicate that the use of mouth-dispersing Ranolazine films can be a noteworthy and inventive therapy option for cardiovascular conditions such as myocardial infarction, angina pectoris, and heart attacks.